Khosla Ventures

Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.

Overture Life, Inc. is a biotechnology company based in New York, established in 2017, that specializes in developing robotic solutions for in vitro fertilization (IVF) applications. The company focuses on automating the IVF process through innovative medical devices and embryo testing methodologies, which enhance the efficiency and success rates of fertility treatments. By optimizing resource use and lowering costs, Overture Life aims to make IVF more accessible to a broader audience. Its technology includes automated cryopreservation and embryo testing services, enabling fertility clinics to identify viable embryos prior to implantation, thereby improving patient outcomes and supporting individuals in their journey to parenthood.

Even partners with top hospitals nationwide to offer unlimited diagnostics, consultations, and hospitalization coverage worth INR 50 lakhs via a single monthly subscription.

Synex Medical is a company focused on advancing health monitoring technology through non-invasive blood testing. It has developed a portable device that utilizes a miniaturized magnetic resonance system to measure blood metabolites without the need for skin penetration. This innovative approach employs only magnets and radio waves, ensuring no adverse health effects for users. By accurately measuring critical metabolites such as glucose, lactate, and ketones, Synex Medical's technology empowers individuals to monitor their health proactively and make informed decisions about their well-being.

Neurode develops a non-invasive wearable headset and companion software to treat and monitor ADHD-related symptoms by delivering electrical stimulation to balance brain activity, targeting cognitive functions such as working memory, attention, and impulse control. The drug-free approach supports medical professionals in improving cognitive performance, while the paired app tracks progress and shares data with clinicians for ongoing assessment and adjustment of treatment.

Inflammatix develops rapid molecular diagnostics tests that interpret the immune system to resolve major clinical challenges. Initially focused on acute bacterial and viral infections, sepsis, and other conditions like tropical infections and autoimmune diseases.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Openwater is a medical technology startup founded in 2016 and based in San Francisco, California. The company specializes in developing advanced wearable devices that utilize novel optoelectronics to achieve MRI-like resolution for medical diagnostics and treatments. By employing LCDs with small pixels, Openwater's technology creates holographic images that reduce scattering, enabling physicians to visualize the inner workings of the body and brain at a cellular level. This innovation allows for precise diagnosis and targeted treatment of diseases by manipulating or destroying individual cells without damaging surrounding tissue. Openwater aims to revolutionize medical imaging and improve patient outcomes through its cutting-edge approach.

Even partners with top hospitals nationwide to offer unlimited diagnostics, consultations, and hospitalization coverage worth INR 50 lakhs via a single monthly subscription.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.

Founded in London in 2017, Limbic specializes in developing software solutions for mental health. They create AI-driven agents to assist in patient intake, triage, screening, and therapy, aiming to enhance the efficiency of healthcare providers and improve patient outcomes.

Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.

Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies. Its platform cultures human tissues in labs for realistic preclinical drug testing, using advanced AI to accelerate the creation of safe and effective therapeutics.

Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

Even partners with top hospitals nationwide to offer unlimited diagnostics, consultations, and hospitalization coverage worth INR 50 lakhs via a single monthly subscription.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Ultima Genomics is a biotechnology company established in 2016 and headquartered in Newark, California. It specializes in genome-scale sequencing technology, focusing on providing analytical services to various enterprises. By employing an open substrate, Ultima Genomics creates a vast, low-cost reaction surface that facilitates billions of reads without relying on expensive flow cells or complex fluidic systems. The company utilizes specialized sequencing hardware combined with machine learning techniques to ensure reproducible and accurate results. This innovative approach enables clients to obtain genomic reports at scale, enhancing the speed and efficiency of sequencing while significantly reducing costs. Ultima Genomics aims to harness the potential of genomic information to drive advancements in biology and improve human health.

Oobli develops healthy, low-calorie protein sweeteners derived from exotic plants. These rare compounds offer great taste without affecting blood sugar levels or gut microbiome. The company has secured regulatory approvals such as FDA 'no questions' letters and GRAS status for multiple proteins.

COR helps you implement globally-proven healthy lifestyle practices, then shows you a totally new type of data about how your body responds. Optimize your lifestyle and discover the impact of different daily customs with precise, science-based self-knowledge.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.

Known Medicine Inc. is a biotechnology company based in Salt Lake City, Utah, founded in 2020. The company specializes in developing a custom organoid platform designed for tumor sensitivity testing through advanced bioengineering techniques. Known Medicine focuses on transforming the process of evaluating how tumors respond to cancer therapies by taking tumor samples and breaking them down into microtumors. These microtumors are treated in specialized micro-environments using various methods to ascertain the most effective treatment options. The company's platform integrates machine learning with omics data to identify predictive biomarkers that inform oncologists about cancer cell behavior and potential treatment pathways, ultimately aiming to enhance personalized cancer care.

Deep Genomics is a Toronto-based company founded in 2014. It specializes in developing individualized genetic medicines using artificial intelligence systems to accelerate drug discovery and development processes, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company focuses on therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders, utilizing oligonucleotide therapies that target genetic determinants of disease at the RNA or DNA level.

Even partners with top hospitals nationwide to offer unlimited diagnostics, consultations, and hospitalization coverage worth INR 50 lakhs via a single monthly subscription.

Founded in 2013, Ellipsis Health is a technology company that uses artificial intelligence to improve behavioral health. It analyzes patient speech and clinical data to predict health outcomes and provide real-time assessments for conditions like depression.

Hello Heart Inc., established in 2013 and headquartered in Redwood City, California, specializes in developing digital health solutions. Its flagship product is Hello Heart, a mobile application designed to empower individuals to manage their heart health effectively. The app enables users to track their blood pressure and weight, providing real-time personalized tips based on clinical guidelines. Employers can also utilize this platform to proactively manage employee health risks associated with high blood pressure, fostering behavior change and preventing serious health issues.

Overture Life, Inc. is a biotechnology company based in New York, established in 2017, that specializes in developing robotic solutions for in vitro fertilization (IVF) applications. The company focuses on automating the IVF process through innovative medical devices and embryo testing methodologies, which enhance the efficiency and success rates of fertility treatments. By optimizing resource use and lowering costs, Overture Life aims to make IVF more accessible to a broader audience. Its technology includes automated cryopreservation and embryo testing services, enabling fertility clinics to identify viable embryos prior to implantation, thereby improving patient outcomes and supporting individuals in their journey to parenthood.

DocBot, Inc. is an artificial intelligence technology company based in Irvine, California, specializing in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices that serve as a clinical decision support system, aggregating patient information and providing cloud analytics to healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which offers real-time image analysis, automated reporting, and analytical tools aimed at enhancing patient care and clinical workflows. By integrating various data sources from imaging systems to pathology requisitions, DocBot's platform aids physicians in detecting colorectal cancer and other gastrointestinal conditions, ultimately striving to improve healthcare outcomes and reduce patient risks.

Apton Biosystems, Inc. is a biotechnology company based in Pleasanton, California, founded in 2012. The company specializes in developing advanced optical systems for sequencing and protein detection, utilizing super-resolution technology to analyze molecules that are spaced closer than the wavelength of light. This innovative approach facilitates multi-omic sequencing and single-molecule protein detection, significantly enhancing capabilities in biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems aims to advance preventive health and precision medicine by addressing spatial challenges in high-density sequencing and protein analysis, thus contributing to improved healthcare outcomes.

Quadrant Eye is an innovative company focused on transforming the field of online eye care. It has developed a platform that facilitates instant and reliable remote eye examinations, allowing patients to screen, diagnose, and manage both low-acuity and chronic eye conditions from the comfort of their homes. The platform addresses a range of eye health issues, including cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy. By providing accessible services for conditions such as diabetic eye disease and nearsightedness, Quadrant Eye aims to enhance patient care and streamline the treatment process for various ocular health concerns.

StimScience develops non-invasive brain stimulation technologies, including transcranial direct current stimulation, transcranial alternating current stimulation, and transcranial random noise stimulation. Its NeuroMod tXES platform enables users to generate arbitrary waveforms for tailored tES applications. Founded in 2017 and based in Berkeley, California, StimScience focuses on commercializing neuroscience and sleep research into products and services for individuals, employers, and health plans. The team comprises leading sleep and neuroscience researchers and advisors, with early funding supporting the launch of Somnee, an advanced diagnostic and therapeutic product designed to help people fall asleep faster and achieve higher-quality restorative sleep. Sleep health is central to mental health, memory, learning, and physical well-being.

Rightway is a technology-driven healthcare company that focuses on care navigation and pharmacy benefit management. It offers a platform and services that guide members to appropriate care and therapies, with dedicated clinical guides and personalized support. By providing transparent pharmacy benefits and decision support, Rightway aims to help healthcare organizations reduce total cost of care while improving member engagement and access to high-value care. The company's platform reimagines the member experience by simplifying interactions, enhancing visibility into benefits, and facilitating more informed choices. Through its care navigation and PBM solutions, Rightway seeks to lower healthcare spending for clients and members by directing them to optimal care pathways and cost-effective treatments. The business combines technology with clinical guidance to streamline benefits administration, support member decision making, and drive better health outcomes.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

Inflammatix develops rapid molecular diagnostics tests that interpret the immune system to resolve major clinical challenges. Initially focused on acute bacterial and viral infections, sepsis, and other conditions like tropical infections and autoimmune diseases.

Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.

Earli is a biotechnology company focused on advancing cancer detection and treatment through innovative technology. The company specializes in developing devices that utilize a novel gene therapy approach known as Synthetic Biopsy. This method compels cancer cells to produce synthetic biomarkers, which are not naturally occurring in the human body. These biomarkers can then be detected in bodily fluids such as blood, urine, or breath, allowing for early identification of cancer. By facilitating the early detection of homogeneous tumors, Earli aims to significantly improve the chances of successful treatment and personalize therapy options for patients. Additionally, the technology is designed to be visible during imaging procedures such as PET scans, enhancing the monitoring of cancer progression and treatment efficacy.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company specializes in providing affordable primary care through a chat-based interface that integrates artificial intelligence with human clinicians. This approach leverages advanced machine learning tools to streamline patient interactions and enhance diagnostic accuracy. By creating a responsive learning healthcare system, Curai Health aims to make high-quality primary care accessible to everyone, reducing the overall cost of care delivery. The service is available directly to consumers and can also be accessed through enterprise partnerships, emphasizing its commitment to improving healthcare accessibility and affordability.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.

Invoy is a company focused on enhancing health and weight loss outcomes through the integration of science, data, and artificial intelligence. It develops a monitoring medical device that offers personalized nutrition and wellness services by generating real-time data on an individual's metabolism. This device not only provides tailored, predictive nutrition recommendations but also features affordable breath analyzers for medical applications. By addressing the unique body chemistry of each individual, Invoy aims to empower users to achieve their specific health and wellness objectives.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

Oobli develops healthy, low-calorie protein sweeteners derived from exotic plants. These rare compounds offer great taste without affecting blood sugar levels or gut microbiome. The company has secured regulatory approvals such as FDA 'no questions' letters and GRAS status for multiple proteins.

Caption Health, Inc. is a technology company specializing in artificial intelligence software designed to enhance the acquisition and interpretation of ultrasound exams. Its flagship product, Caption AI, serves as an AI-guided medical imaging acquisition system that assists healthcare providers by offering real-time guidance, automating quality assessments, and interpreting ultrasound images to ensure diagnostic accuracy. Founded in 2013 and headquartered in Brisbane, California, Caption Health was previously known as Bay Labs, Inc. The company aims to scale its commercial operations and further develop its AI technology platform, intending to broaden the application of Caption AI across various clinical settings as adoption increases among healthcare practitioners.

Siren Care develops wearable health technology for diabetic foot health monitoring. The company offers Siren diabetic socks and a foot temperature monitoring system that continuously tracks foot temperature to detect early signs of inflammation and diabetic foot ulcers, helping prevent complications such as amputations. Data from the socks can be accessed via a mobile application and shared with providers, including podiatrists, to support monitoring and timely intervention. It serves patients and healthcare providers through its flagship Siren Diabetic Foot Program. Founded in 2015 and based in San Francisco, Siren Care focuses on proactive foot health management for individuals at risk of diabetic foot complications.

Yes Health designs a mobile application offering personalized nutrition, fitness, and diabetes-prevention advice. Its team of physicians, health coaches, and engineers creates engaging programs for users to adopt healthier lifestyles, prevent diabetes onset, and manage symptoms effectively.

E25Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018, that focuses on developing rapid diagnostic tests for epidemic fever viruses. The company designs paper-based diagnostic systems and kits that facilitate the detection of viruses such as dengue, chikungunya, and Zika. E25Bio's innovative platform enables multiplexed testing that quickly identifies viral antigens during infections, allowing for real-time data reporting through a mobile application. This capability supports epidemiologic predictions and disease mapping, empowering governments and health organizations to respond effectively to outbreaks and manage public health crises. Through its commitment to fast, mobile testing solutions, E25Bio aims to prevent severe health outcomes associated with viral epidemics.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Inflammatix develops rapid molecular diagnostics tests that interpret the immune system to resolve major clinical challenges. Initially focused on acute bacterial and viral infections, sepsis, and other conditions like tropical infections and autoimmune diseases.

Deep Genomics is a Toronto-based company founded in 2014. It specializes in developing individualized genetic medicines using artificial intelligence systems to accelerate drug discovery and development processes, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company focuses on therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders, utilizing oligonucleotide therapies that target genetic determinants of disease at the RNA or DNA level.

Ginger.io, Inc. is a digital mental health provider that offers a behavioral analytics platform designed to deliver on-demand mental healthcare via mobile devices. Founded in 2010 and headquartered in San Francisco, California, the platform connects users with a team of behavioral health coaches, therapists, and psychiatrists, facilitating personalized care accessible 24/7. Users can collect and analyze both passive and active behavioral data, enabling the identification of health insights and deviations from normal behavior. This service is utilized by a wide range of clients, including researchers, healthcare providers, and millions of employees through partnerships with leading employers and health plans. Ginger's approach focuses on providing immediate support and evidence-based interventions for individuals experiencing mental health challenges such as depression and anxiety.

Hello Heart Inc., established in 2013 and headquartered in Redwood City, California, specializes in developing digital health solutions. Its flagship product is Hello Heart, a mobile application designed to empower individuals to manage their heart health effectively. The app enables users to track their blood pressure and weight, providing real-time personalized tips based on clinical guidelines. Employers can also utilize this platform to proactively manage employee health risks associated with high blood pressure, fostering behavior change and preventing serious health issues.

Overture Life, Inc. is a biotechnology company based in New York, established in 2017, that specializes in developing robotic solutions for in vitro fertilization (IVF) applications. The company focuses on automating the IVF process through innovative medical devices and embryo testing methodologies, which enhance the efficiency and success rates of fertility treatments. By optimizing resource use and lowering costs, Overture Life aims to make IVF more accessible to a broader audience. Its technology includes automated cryopreservation and embryo testing services, enabling fertility clinics to identify viable embryos prior to implantation, thereby improving patient outcomes and supporting individuals in their journey to parenthood.

Tempo designs and develops a home fitness platform with personal guidance to help users in their training sessions. It features live elite trainers who can help users when they make mistakes. It has built-in three-dimensional sensors that track form, counts reps, and recommend weights. It helps users to improve in real-time. Powered by 3D motion sensors and AI, it analyzes 25 of the body’s essential joints as users work out and gives understood form feedback. Moawia Eldeeb and Joshua Augustin founded it as Pivot in 2015, with its headquarters in San Francisco in California.

Probably Genetic is a company that provides genetic testing services to diagnose rare genetic conditions, including those often initially misdiagnosed as autism spectrum disorder. It enables at-home saliva sample collection and performs comprehensive DNA sequencing analysis, accompanied by personalized counseling to help patients and families obtain accurate diagnoses and access relevant clinical treatments. By offering educational materials and streamlined testing, the company aims to shorten diagnostic journeys and support individuals who fall through gaps in the healthcare system.

Neurotrack is a digital health company focused on the early detection and management of Alzheimer's disease and other dementias. It offers turnkey cognitive assessment platforms for providers to facilitate rapid, patient-guided screening and ongoing monitoring of cognitive function, usable in clinic or at home to fit diverse workflows. The platform employs eye-tracking technology and culturally-agnostic symbols to deliver rapid assessments with instant, objective scoring integrated with electronic health records, and supports remote and in-clinic administration, ongoing monitoring tools, and educational resources addressing modifiable risk factors. Neurotrack has published peer-reviewed research, holds patents on its proprietary technology, and has FDA Class II medical device status. Founded in 2012 and based in Redwood City, California.

Founded in 2017, Daye is a London-based company dedicated to improving women's gynecological health. It manufactures and markets innovative tampon products, including CBD-infused options for period pain relief, and offers an at-home vaginal microbiome screening kit to detect infections and microbiome disruptions.

DocBot, Inc. is an artificial intelligence technology company based in Irvine, California, specializing in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices that serve as a clinical decision support system, aggregating patient information and providing cloud analytics to healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which offers real-time image analysis, automated reporting, and analytical tools aimed at enhancing patient care and clinical workflows. By integrating various data sources from imaging systems to pathology requisitions, DocBot's platform aids physicians in detecting colorectal cancer and other gastrointestinal conditions, ultimately striving to improve healthcare outcomes and reduce patient risks.

StimScience develops non-invasive brain stimulation technologies, including transcranial direct current stimulation, transcranial alternating current stimulation, and transcranial random noise stimulation. Its NeuroMod tXES platform enables users to generate arbitrary waveforms for tailored tES applications. Founded in 2017 and based in Berkeley, California, StimScience focuses on commercializing neuroscience and sleep research into products and services for individuals, employers, and health plans. The team comprises leading sleep and neuroscience researchers and advisors, with early funding supporting the launch of Somnee, an advanced diagnostic and therapeutic product designed to help people fall asleep faster and achieve higher-quality restorative sleep. Sleep health is central to mental health, memory, learning, and physical well-being.

Loop Genomics develops long-read DNA sequencing technology that enables existing short-read instruments to perform high-throughput, phased, single-molecule sequencing. The company provides consumables and analysis tools to extend sequencing capabilities across research, diagnostics, agriculture-biotech, and industrial applications, allowing laboratories to access long-read sequencing without new platforms. Its technology supports full-length, phased sequencing of microbial communities to improve microbiome profiling by capturing all variable regions, and enables accurate phased sequencing of human leukocyte antigen genes to reduce diploid ambiguity for transplantation testing and association studies. In virology, it maps viral genetic variability at the quasi-species level to identify mutations and inform therapy and vaccine strategies. By delivering high-throughput, phased data with existing infrastructure, Loop Genomics clarifies complex genetic signals.

Siren Care develops wearable health technology for diabetic foot health monitoring. The company offers Siren diabetic socks and a foot temperature monitoring system that continuously tracks foot temperature to detect early signs of inflammation and diabetic foot ulcers, helping prevent complications such as amputations. Data from the socks can be accessed via a mobile application and shared with providers, including podiatrists, to support monitoring and timely intervention. It serves patients and healthcare providers through its flagship Siren Diabetic Foot Program. Founded in 2015 and based in San Francisco, Siren Care focuses on proactive foot health management for individuals at risk of diabetic foot complications.

Higia Technologies, founded in 2016 and based in Mexico City, specializes in developing EVA, a non-invasive wearable device aimed at assessing breast cancer risk. This innovative device features tactile sensors that map the surface of the breast and its surrounding areas. By continuously monitoring changes in breast temperature, size, and weight through embedded biosensors, EVA empowers women to actively track their breast health. The company's focus is on making breast cancer risk assessment more accessible and user-friendly.

Nebula Genomics is a biotechnology company founded in 2016 and based in San Francisco, California. It specializes in human genome sequencing and the creation of a marketplace for genomic and health data aimed at consumers, researchers, and the medical community. The company's mission is to facilitate genomic sequencing and enhance personalized medicine by aggregating a substantial repository of genetic information. Utilizing blockchain technology, Nebula Genomics ensures that consumers retain control over their data and receive compensation for its use. The marketplace enables researchers to analyze rich genetic datasets, which can accelerate drug development and improve the efficiency of clinical trials. Founded by prominent genomics researcher George Church and his associates, Nebula Genomics offers advanced DNA sequencing technology that allows clients to explore all genes and genetic variants in the genome, thereby providing comprehensive insights into individual health.

Openwater is a medical technology startup founded in 2016 and based in San Francisco, California. The company specializes in developing advanced wearable devices that utilize novel optoelectronics to achieve MRI-like resolution for medical diagnostics and treatments. By employing LCDs with small pixels, Openwater's technology creates holographic images that reduce scattering, enabling physicians to visualize the inner workings of the body and brain at a cellular level. This innovation allows for precise diagnosis and targeted treatment of diseases by manipulating or destroying individual cells without damaging surrounding tissue. Openwater aims to revolutionize medical imaging and improve patient outcomes through its cutting-edge approach.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

Remedy is a prescriptive chronic care analytics platform employing artificial intelligence to help value-based health systems determine who should get what care, when, how, and by whom to maximize patient health outcomes per dollar spent. We are a design-driven company with core medical AI technology capable of diagnosing disease, catching hidden high-risk diagnoses, and projecting the development of patient’s health into the future. Built around our core AI engine, our first product Remedy Sentinel helps value-based providers identify hidden chronic, co-morbid conditions and intervene by engaging high-risk patients prior to onset. We envision a world where healthcare marries the science of “health” with the art of “care”: scientific, data-driven decision making drives the best outcomes for each individual patient, and frees providers to focus on applying their human touch. Remedy combines novel artificial intelligence algorithms for predictive medical analytics with a healthcare-optimized product development process to give leaders the tools they need to transform their delivery networks and thrive in a value-based care environment. With this approach, Remedy builds a scalable suite of products that, when deployed, learn from experience, and grow into a solution optimized to fit the needs of specific provider groups and the populations they serve. Remedy systematically maximizes the patient health outcome achieved with each dollar spent by using AI to help determine what care is delivered to whom, when it is delivered, where it is delivered, how it is delivered, followed, and supported, and who should deliver it. We not only surface insights, but also build the necessary tools and helps coordinate step-by-step implementation processes to affect real change.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Zebra Medical Vision is an Israel-based company that develops an imaging analytics platform for healthcare. The platform supplies clinicians with imaging research tools, provides advanced learning and computer-vision diagnostic algorithms for developers, and offers risk management and preventative care tools for providers. The company also offers researchers access to tools and datasets to accelerate the development of decision-support and diagnostic technologies. Founded in 2014 and headquartered in Shefayim, Zebra Medical Vision collaborates with partners such as USARAD Holdings and TELUS Ventures and has deployed its AI-enabled imaging analytics across hospitals worldwide.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company specializes in providing affordable primary care through a chat-based interface that integrates artificial intelligence with human clinicians. This approach leverages advanced machine learning tools to streamline patient interactions and enhance diagnostic accuracy. By creating a responsive learning healthcare system, Curai Health aims to make high-quality primary care accessible to everyone, reducing the overall cost of care delivery. The service is available directly to consumers and can also be accessed through enterprise partnerships, emphasizing its commitment to improving healthcare accessibility and affordability.

Siren Care develops wearable health technology for diabetic foot health monitoring. The company offers Siren diabetic socks and a foot temperature monitoring system that continuously tracks foot temperature to detect early signs of inflammation and diabetic foot ulcers, helping prevent complications such as amputations. Data from the socks can be accessed via a mobile application and shared with providers, including podiatrists, to support monitoring and timely intervention. It serves patients and healthcare providers through its flagship Siren Diabetic Foot Program. Founded in 2015 and based in San Francisco, Siren Care focuses on proactive foot health management for individuals at risk of diabetic foot complications.

Neurotrack is a digital health company focused on the early detection and management of Alzheimer's disease and other dementias. It offers turnkey cognitive assessment platforms for providers to facilitate rapid, patient-guided screening and ongoing monitoring of cognitive function, usable in clinic or at home to fit diverse workflows. The platform employs eye-tracking technology and culturally-agnostic symbols to deliver rapid assessments with instant, objective scoring integrated with electronic health records, and supports remote and in-clinic administration, ongoing monitoring tools, and educational resources addressing modifiable risk factors. Neurotrack has published peer-reviewed research, holds patents on its proprietary technology, and has FDA Class II medical device status. Founded in 2012 and based in Redwood City, California.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Founded in 2013, Ellipsis Health is a technology company that uses artificial intelligence to improve behavioral health. It analyzes patient speech and clinical data to predict health outcomes and provide real-time assessments for conditions like depression.

Deep Genomics is a Toronto-based company founded in 2014. It specializes in developing individualized genetic medicines using artificial intelligence systems to accelerate drug discovery and development processes, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company focuses on therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders, utilizing oligonucleotide therapies that target genetic determinants of disease at the RNA or DNA level.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Guardant Health is a precision oncology company specializing in blood tests and analytics. It provides liquid biopsy tests like Guardant360 for advanced cancer detection, GuardantOMNI for broader gene panels, LUNAR-1 for minimal residual disease detection, and LUNAR-2 for early cancer detection. The company also offers development services to biopharmaceutical companies.

Ontera develops handheld diagnostic platforms using silicon nanopore chips and proprietary biochemistry. These platforms detect and differentiate single molecules in DNA, RNA, proteins, viruses, antibodies, and other analytes from various life forms. Applications include human and animal diagnostics, agriculture, food safety testing, environmental monitoring, and more.

Inflammatix develops rapid molecular diagnostics tests that interpret the immune system to resolve major clinical challenges. Initially focused on acute bacterial and viral infections, sepsis, and other conditions like tropical infections and autoimmune diseases.

Caption Health, Inc. is a technology company specializing in artificial intelligence software designed to enhance the acquisition and interpretation of ultrasound exams. Its flagship product, Caption AI, serves as an AI-guided medical imaging acquisition system that assists healthcare providers by offering real-time guidance, automating quality assessments, and interpreting ultrasound images to ensure diagnostic accuracy. Founded in 2013 and headquartered in Brisbane, California, Caption Health was previously known as Bay Labs, Inc. The company aims to scale its commercial operations and further develop its AI technology platform, intending to broaden the application of Caption AI across various clinical settings as adoption increases among healthcare practitioners.

Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.

Luminostics, Inc. is a Houston-based company that specializes in developing a smartphone-based adaptor designed for rapid, molecular-level health testing. Founded in 2015, Luminostics focuses on providing a 15-minute do-it-yourself disease testing solution that caters to both healthcare professionals and consumers. The technology allows users to access vital health information conveniently and efficiently, streamlining the process of disease detection and management.

Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.

Zebra Medical Vision is an Israel-based company that develops an imaging analytics platform for healthcare. The platform supplies clinicians with imaging research tools, provides advanced learning and computer-vision diagnostic algorithms for developers, and offers risk management and preventative care tools for providers. The company also offers researchers access to tools and datasets to accelerate the development of decision-support and diagnostic technologies. Founded in 2014 and headquartered in Shefayim, Zebra Medical Vision collaborates with partners such as USARAD Holdings and TELUS Ventures and has deployed its AI-enabled imaging analytics across hospitals worldwide.

Luminist, Inc. is a biomedical company focused on developing a diagnostic platform aimed at the early detection and diagnosis of liver disease. Established in 2015 and located in Newark, California, Luminist operates as a subsidiary of DiscernDx. The company's innovative platform leverages data-driven methodologies to transform biochemical data into essential health information. This enables healthcare providers to deliver comprehensive insights regarding liver diseases and cancer screening through a single diagnostic test, enhancing patient care and facilitating timely medical intervention.

Neurotrack is a digital health company focused on the early detection and management of Alzheimer's disease and other dementias. It offers turnkey cognitive assessment platforms for providers to facilitate rapid, patient-guided screening and ongoing monitoring of cognitive function, usable in clinic or at home to fit diverse workflows. The platform employs eye-tracking technology and culturally-agnostic symbols to deliver rapid assessments with instant, objective scoring integrated with electronic health records, and supports remote and in-clinic administration, ongoing monitoring tools, and educational resources addressing modifiable risk factors. Neurotrack has published peer-reviewed research, holds patents on its proprietary technology, and has FDA Class II medical device status. Founded in 2012 and based in Redwood City, California.

Guardant Health is a precision oncology company specializing in blood tests and analytics. It provides liquid biopsy tests like Guardant360 for advanced cancer detection, GuardantOMNI for broader gene panels, LUNAR-1 for minimal residual disease detection, and LUNAR-2 for early cancer detection. The company also offers development services to biopharmaceutical companies.

CrowdMed, Inc. is a San Francisco-based company that leverages a prediction market technology to assist in diagnosing complex medical conditions. Founded in 2012, CrowdMed aims to provide patients with streamlined access to diagnostic information for their undiagnosed and chronic symptoms. The company's platform connects patients with a diverse network of medical detectives, including licensed physicians, medical students, and other healthcare professionals, who collaborate to generate diagnostic suggestions. By harnessing the collective intelligence of these experts, CrowdMed offers a collaborative solution for individuals facing unresolved medical issues, ultimately aiming to reduce healthcare costs while maintaining quality care. The platform is designed to empower patients by providing them with insightful answers to their medical challenges through the speed and convenience of online interaction.

Klarismo Limited is a health technology company based in London, United Kingdom, that specializes in 3D body analysis using magnetic resonance imaging (MRI). Founded in 2014, it offers a platform that converts full-body MRI scans into detailed 3D virtual models, allowing users to explore their body composition with unprecedented precision. The service provides volumetric measurements of muscle and fat tissues, helping health-conscious consumers and amateur athletes understand their physiological changes over time. With regular MRI scans, Klarismo updates users' 3D models to reflect changes in muscle and fat distribution, facilitating effective monitoring of fitness and dietary progress. In addition to serving individual users, the company assists private medical imaging centers in optimizing their resources and builds a database of full-body MRI scans for medical research purposes.

Tempo designs and develops a home fitness platform with personal guidance to help users in their training sessions. It features live elite trainers who can help users when they make mistakes. It has built-in three-dimensional sensors that track form, counts reps, and recommend weights. It helps users to improve in real-time. Powered by 3D motion sensors and AI, it analyzes 25 of the body’s essential joints as users work out and gives understood form feedback. Moawia Eldeeb and Joshua Augustin founded it as Pivot in 2015, with its headquarters in San Francisco in California.

Zebra Medical Vision is an Israel-based company that develops an imaging analytics platform for healthcare. The platform supplies clinicians with imaging research tools, provides advanced learning and computer-vision diagnostic algorithms for developers, and offers risk management and preventative care tools for providers. The company also offers researchers access to tools and datasets to accelerate the development of decision-support and diagnostic technologies. Founded in 2014 and headquartered in Shefayim, Zebra Medical Vision collaborates with partners such as USARAD Holdings and TELUS Ventures and has deployed its AI-enabled imaging analytics across hospitals worldwide.

Apton Biosystems, Inc. is a biotechnology company based in Pleasanton, California, founded in 2012. The company specializes in developing advanced optical systems for sequencing and protein detection, utilizing super-resolution technology to analyze molecules that are spaced closer than the wavelength of light. This innovative approach facilitates multi-omic sequencing and single-molecule protein detection, significantly enhancing capabilities in biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems aims to advance preventive health and precision medicine by addressing spatial challenges in high-density sequencing and protein analysis, thus contributing to improved healthcare outcomes.

Guardant Health is a precision oncology company specializing in blood tests and analytics. It provides liquid biopsy tests like Guardant360 for advanced cancer detection, GuardantOMNI for broader gene panels, LUNAR-1 for minimal residual disease detection, and LUNAR-2 for early cancer detection. The company also offers development services to biopharmaceutical companies.